All In Biotech

Drug Trial Radar · NCT07011667

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 609 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

609

Actual

Start

Jun 3, 2025

Primary completion

Mar 1, 2027

Study completion Oct 17, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.

Conditions

  • Obesity

Interventions

  • CagriSema (Cagrilintide B and Semaglutide I)Drug

    CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.

  • Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Drug

    Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to week 80

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • FDRC

    Costa Mesa, California

  • Linda Vista Health Care Ctr

    San Diego, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Northeast Research Institute

    Fleming Island, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Florida Inst For Clin Res LLC

    Orlando, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida

  • Hope Clin Res & Wellness

    Conyers, Georgia

  • Endocrine Research Solutions

    Roswell, Georgia

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Evanston Premier Hlthcr Res

    Skokie, Illinois

  • Midwest Inst For Clin Res

    Indianapolis, Indiana

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Amicis Centers of Clinical Research

    St Louis, Missouri

  • Mercury Str Med Grp, PLLC

    Butte, Montana

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Great Lakes Medical Research

    Westfield, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Medication Mgmnt, LLC_Grnsboro

    Greensboro, North Carolina

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina

  • Accellacare_NC

    Raleigh, North Carolina

  • Piedmont Healthcare/Research

    Statesville, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • New Venture Medical Research

    Wadsworth, Ohio

  • Lynn Institute of Norman

    Norman, Oklahoma

  • Clinical Res Collaborative

    Cumberland, Rhode Island

  • Coastal Carolina Res Ctr

    North Charleston, South Carolina

  • Hillcrest Clinical Research

    Simpsonville, South Carolina

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Holston Medical Group

    Kingsport, Tennessee

  • Clinical Research Associates

    Nashville, Tennessee

  • Amarillo Medical Specialists

    Amarillo, Texas

  • Velocity Clin Res, Dallas

    Dallas, Texas

  • PlanIt Research, PLLC

    Houston, Texas

  • Radiance Clinical Research

    Lampasas, Texas

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.